^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Serine protease inhibitor

    Related drugs:
    4d
    Comparison of Anticoagulant Effects Between Nafamostat Mesylate and Sodium Citrate in Double Filtration Plasmapheresis (ChiCTR2600117445)
    P=N/A, N=140, Not yet recruiting, The First Affiliated Hospital of Army Medical University PLA; The First Affiliated Hospital of Army Medical University PLA
    New trial
    |
    nafamostat
    4d
    A Randomized, Active-Controlled, Open-Label Clinical Study of Nafamostat Mesylate for Reducing Bleeding Risk in Maintenance Hemodialysis Patients at High Risk of Bleeding (ChiCTR2600116304)
    P=N/A, N=338, Not yet recruiting, The Seventh Affiliated Hospital Sun Yat-sen University; The Seventh Affiliated Hospital of Sun Yat-sen University
    New trial
    |
    nafamostat • enoxaparin sodium
    7d
    HSP90α and KLK6 Coregulate Stress-Induced Prostate Cancer Cell Motility. (PubMed, Cells)
    Screening for protease inhibitors that would rescue stress-induced decreases in MMP-2 activity identified a single serine protease inhibitor: aprotinin...In conclusion, we identify a novel stress-induced extracellular network that regulates MMP-2 activity and cell motility. We identified KLK6 as a stress-induced extracellular protease leading to decreased MMP-2 activity and cellular invasion, while eHSP90α is required for the rescue of MMP-2 activity once KLK6 is neutralized.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • KLK6 (Kallikrein Related Peptidase 6)
    8d
    Exploring Molecular Signature and Prognostic Biomarkers in Ovarian Cancer: Insights From Late-Stage, Recurrent, and Metastatic Tumors. (PubMed, Biotechnol Appl Biochem)
    Ocriplasmin and pamidronate were identified as potential therapeutics. Our findings highlight the therapeutic relevance of these hub genes and identify them as potential drug targets and prognostic biomarkers in ovarian cancer.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • IGF1 (Insulin-like growth factor 1) • FN1 (Fibronectin 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • COL3A1 (Collagen Type III Alpha 1 Chain) • MIR29A (MicroRNA 29a) • POSTN (Periostin)
    |
    pamidronate disodium
    18d
    Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery (clinicaltrials.gov)
    P4, N=160, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    25d
    Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery (clinicaltrials.gov)
    P1, N=604, Recruiting, Rush University Medical Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    26d
    HSP90α and KLK6 Co-Regulate Stress-Induced Prostate Cancer Cell Motility. (PubMed, bioRxiv)
    Screening for protease inhibitors that would rescue stress-induced decreases in MMP-2 activity identified a single serine protease inhibitor: aprotinin...We identify a novel stress-induced extracellular network that regulates MMP-2 activity and cell motility. We identified KLK6 as a stress-induced extracellular protease leading to decreased MMP-2 activity and cellular invasion, while eHSP90α is required for the rescue of MMP-2 activity once KLK6 is neutralized.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • KLK6 (Kallikrein Related Peptidase 6)
    28d
    Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone (clinicaltrials.gov)
    P=N/A, N=80, Not yet recruiting, Cairo University
    New trial
    1m
    Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial (clinicaltrials.gov)
    P3, N=826, Active, not recruiting, Bayside Health | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> Aug 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    2ms
    Dose-Dependent Effects of Intraoperative Tranexamic Acid on Surgical Bleeding and Transfusion Requirements in Multilevel Thoracolumbar Spinal Surgery (clinicaltrials.gov)
    P=N/A, N=62, Completed, Dr. Lutfi Kirdar Kartal Training and Research Hospital
    New trial
    2ms
    The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery (clinicaltrials.gov)
    P4, N=150, Recruiting, Montefiore Medical Center | Suspended --> Recruiting
    Enrollment open
    2ms
    Effect of extracorporeal anticoagulation with nafamostat mesilate and continuous renal replacement therapy on sepsis complicated with acute kidney injury. (PubMed, Int J Clin Pharmacol Ther)
    NM outperforms RCA in prolonging the hemofilter lifespan, reducing hemofilter replacement frequency, improving renal perfusion and renal function, and eliminating inflammatory mediators.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    nafamostat